We have two unique products that are ground breaking in various cancer treatment
Tumor defence breaker
DOS47 is a patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cells. DOS47 is designed to offer a means of deriving a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. The technology is based on the principle of using an enzyme to catalyse the metabolism (catabolism) of an endogenous substrate molecule in order to yield metabolites of therapeutic benefit.
For more information, please click here
Tumor attack agent
The Company is leveraging its know-how in manipulating the tumour microenvironment, and its expertise in developing unique single domain antibody therapeutics to develop Chimeric Antigen Receptors (“CAR”) for engineered T cell based treatment (“CAR-T”). CAR-T is a novel cell based treatment that uniquely leverages the patient’s immune system to treat cancer. In one application, the patient’s T cells are isolated and then transformed with specific CAR that recognize the cancer. The transformed T cells or CAR-Ts are infused back into the patient to effect the treatment.
Canada and Poland
Heman Chao - CEO
Biochemist with expertise in protein drug development. Previous role with Sensium Technologies Inc.
Frank Michalargias - CFO
Public company CFO with broad industry experience including senior positions with Unilever and Huhtamaki Oy
Paweł Wiśniewski - CEO Poland
Biochemistry background; co-founder Institute of Genetic Analysis